Expanding Product Areas in the Medical Device Business and Addressing Demand from an Aging Population
First written in FY2016. 22 of 40 entries say "Advanced", first in FY2017. Latest entry: 2026-08-05.
3 other companies' latest entry also says "Restated".
- 2026-08-05RestatedEarnings
「As a result of actively pursuing sales expansion, net sales increased 8.5% year on year to ¥1,376 million. In terms of profit, operating profit increased 6.7% year on year to ¥45 million as a result of promoting profitability improvement activities.」
The company continued sales expansion and profitability improvement activities in medical equipment, resulting in increases in both net sales and operating profit. - FY2026AdvancedAnnual report
「In the nonvascular treatment field, the company filed for approval of Japan's first biodegradable esophageal stent that is absorbed by the body and obtained approval. It is working toward determining a new reimbursement price. To further expand overseas sales of endoscopic guidewires, the company is working on compliance with, testing for and validation against the latest international standards. It also began reselling the covered biliary stent カバードバイルラッシュアドバンス.」
Medical device product development advanced through approval of the biodegradable esophageal stent, preparations for overseas expansion of guidewires and the launch of resales of the covered biliary stent. - FY2026-H1RestatedAnnual report
「Although the company actively promoted sales expansion, sales were ¥2,529 million, down 3.9% year on year. On the profit side, operating profit was ¥83 million, down 63.0% year on year, due to lower contribution margin resulting from lower sales and higher labor costs, among other factors.」
The company continued to expand medical device sales, but sales fell 3.9% year on year and operating profit fell 63.0% due to lower sales and higher labor costs, among other factors. - FY2025AdvancedAnnual report
「As a result of actively promoting sales expansion, sales were ¥5,172 million, an increase of ¥423 million, or 8.9%, from the previous fiscal year. On the profit side, operating profit was ¥328 million, an increase of ¥283 million, or 631.3%, from the previous fiscal year, reflecting higher contribution margin from increased sales and the promotion of cost-reduction initiatives.」
The medical device business made significant progress, with sales up 8.9% and operating profit up 631.3% as a result of sales expansion and cost-reduction initiatives. - FY2025-H1AdvancedAnnual report
「(Medical devices) As a result of actively promoting sales expansion, sales were ¥2,633 million, up 16.2% year on year. On the profit side, operating profit was ¥226 million, compared with an operating loss of ¥55 million in the previous year, reflecting higher contribution margin from increased sales and the promotion of cost-reduction initiatives.」
Sales increased 16.2% year on year due to expanded medical device sales, while operating profit improved from an operating loss of ¥55 million in the previous year to operating profit of ¥226 million, supported by cost-reduction initiatives. - FY2024AdvancedAnnual report
「To develop guidewires for gastrointestinal endoscopy as a core technology and enhance competitiveness, the company is introducing new materials and manufacturing equipment and building up its technological expertise. By incorporating some of these technologies, it commercialized multiple types of endoscopic guidewire in FY2023. For products used in intravascular treatment, the company is pursuing applications overseas for the emulsion connector パイオラックスエマルションコネクター, which is expected to improve treatment outcomes by increasing the rate of anticancer drug emulsion formation. The product's domestic name is マイクロマジック. Sales began sequentially in countries where certification was obtained.」
The company commercialized multiple types of endoscopic guidewire in FY2023 and began selling the emulsion connector in countries where certification had been obtained. Its medical device product fields and overseas expansion made concrete progress. - FY2024-Q3AdvancedAnnual report
「As a result of actively promoting sales expansion, sales were ¥3,544 million, up 9.0% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was a ¥13 million loss, compared with operating profit of ¥62 million in the previous fiscal year, mainly due to higher procurement component costs, inventory write-offs and other factors.」
Sales increased 9.0% year on year due to expanded medical device sales. Operating profit, meanwhile, deteriorated from operating profit of ¥62 million in the previous year to an operating loss of ¥13 million due to higher procurement component costs, inventory write-offs and other factors. - FY2024-Q2AdvancedAnnual report
「As a result of actively promoting sales expansion, sales were ¥2,267 million, up 5.4% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was a ¥55 million loss, compared with operating profit of ¥101 million in the previous fiscal year, mainly due to higher component procurement costs, inventory write-offs and other factors.」
Sales increased 5.4% year on year due to expanded medical device sales. Operating profit, meanwhile, deteriorated from operating profit of ¥101 million in the previous year to an operating loss of ¥55 million due to higher component procurement costs, inventory write-offs and other factors. - FY2024-Q1RestatedAnnual report
「(Medical devices) As a result of actively promoting sales expansion, sales were ¥1,143 million, up 0.1% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was a ¥24 million loss, compared with operating profit of ¥65 million in the previous fiscal year, mainly due to the impact of higher component procurement costs and other factors.」
The company continued to expand medical device sales and pursue cost-reduction initiatives. Sales increased 0.1% year on year, while higher component procurement costs and other factors resulted in an operating loss. - FY2023RestatedAnnual report
「To develop guidewires for gastrointestinal endoscopy as a core technology and enhance competitiveness, the company is introducing new materials and manufacturing equipment and building up its technological expertise. By incorporating some of these technologies, it plans to commercialize multiple types of endoscopic guidewire in FY2023.」
The company outlined plans to introduce new materials and manufacturing equipment and commercialize endoscopic guidewires, continuing to expand its medical device product fields. - FY2023-Q3RestatedAnnual report
「(Medical devices) Although the company actively promoted sales expansion, sales were ¥3,252 million, down 6.7% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥62 million, down 72.7% year on year.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 6.7% year on year and operating profit fell 72.7%. - FY2023-Q2RestatedAnnual report
「(Medical devices) Although the company actively promoted sales expansion, sales were ¥2,150 million, down 6.2% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥101 million, down 49.5% year on year, mainly due to the impact of lower inventories and other factors.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 6.2% year on year and operating profit fell 49.5%. No new milestones, such as a new product launch, were indicated. - FY2023-Q1AdvancedAnnual report
「(Medical devices) As a result of actively promoting sales expansion, sales were ¥1,142 million, up 7.3% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥65 million, down 25.8% year on year, mainly due to the impact of lower inventories and other factors.」
Sales increased 7.3% year on year due to expanded medical device sales. Operating profit, meanwhile, fell 25.8% due to the impact of lower inventories and other factors. - FY2022AdvancedAnnual report
「To develop guidewires for gastrointestinal endoscopy as a core technology and enhance competitiveness, the company is introducing new materials and manufacturing equipment and building up its technological expertise. By incorporating some of these technologies, it launched 1 type of endoscopic guidewire, シークマスター035H.」
The company proceeded with the introduction of new materials and manufacturing equipment and launched 1 type of endoscopic guidewire, シークマスター035H. - FY2022-Q3AdvancedAnnual report
「As a result of actively promoting sales expansion, sales were ¥3,485 million, up 13.3% year on year. On the profit side, the company decided to conduct a voluntary recall after defects were identified in some products and recorded the resulting costs. Nevertheless, operating profit was ¥230 million, up 72.4% year on year, reflecting higher sales and the promotion of cost-reduction initiatives.」
Sales increased 13.3% year on year due to expanded medical device sales, while operating profit also increased 72.4% as a result of cost-reduction initiatives and other measures. Meanwhile, the company decided to conduct a voluntary recall due to defects in some products and recorded the related costs. - FY2022-Q2AdvancedAnnual report
「As a result of actively promoting sales expansion, sales were ¥2,291 million, up 13.1% year on year. On the profit side, operating profit was ¥201 million, up 98.0% year on year, reflecting the promotion of cost-reduction initiatives and other measures.」
Sales increased 13.1% year on year due to expanded medical device sales, while operating profit also increased 98.0% as a result of cost-reduction initiatives and other measures. - FY2022-Q1AdvancedAnnual report
「As a result of actively promoting sales expansion, sales were ¥1,064 million, up 4.0% year on year. On the profit side, operating profit was ¥88 million, up 34.5% year on year, reflecting the promotion of cost-reduction initiatives and other measures.」
Sales increased 4.0% year on year due to expanded medical device sales, while operating profit also increased 34.5% as a result of cost-reduction initiatives and other measures. - FY2021AdvancedAnnual report
「A new development system compliant with FDA standards, the US government agency equivalent to Japan's Ministry of Health, Labour and Welfare, has become established, creating a structure capable of commercializing products as planned, including in terms of launch timing, planned features and stable quality. The company has transformed its structure to enable efficient product development and will continue developing distinctive products. The following 4 products were commercialized in FY2020.」
The company explained that its FDA standards-compliant development system had become established, creating a structure capable of commercializing products as planned. It commercialized 4 medical devices in FY2020, including 1 product designated for strengthened sales in FY2021. - FY2021-Q3RestatedAnnual report
「Although the company actively promoted sales expansion, sales were ¥3,076 million, down 5.3% year on year, due to the curtailment of sales activities associated with the coronavirus disease and other factors. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥133 million, down 10.4% year on year, mainly due to a decline in contribution margin resulting from lower sales.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 5.3% year on year and operating profit fell 10.4% due to the curtailment of sales activities associated with the infection and other factors. - FY2021-Q2RestatedAnnual report
「(Medical devices) Although the company actively promoted sales expansion, sales were ¥2,026 million, down 5.8% year on year, due to the curtailment of sales activities associated with the coronavirus disease and other factors. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥101 million, down 16.7% year on year, mainly due to a decline in contribution margin resulting from lower sales.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 5.8% and operating profit fell 16.7% due to the curtailment of sales activities associated with the infection and other factors. - FY2021-Q1RestatedAnnual report
「Although the company actively promoted sales expansion, sales were ¥1,023 million, down 5.6% year on year, due to the curtailment of sales activities associated with the coronavirus disease and other factors. On the profit side, operating profit was ¥65 million, up 3.2% year on year, reflecting the promotion of cost-reduction initiatives and other measures.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 5.6% year on year due to the curtailment of sales activities associated with the novel coronavirus disease and other factors. Operating profit, meanwhile, increased 3.2%. - FY2020AdvancedAnnual report
「The following 4 products were commercialized in FY2019.」
The company commercialized 4 medical devices in FY2019. Of these, レボウェーブPX obtained the CE mark and US approval and began sales in the United States. シークマスター was commercialized in the second half of FY2019 and positioned as a product for strengthened sales in FY2020. - FY2020-Q3RestatedAnnual report
「(Medical devices) As a result of actively promoting sales expansion, sales were ¥3,249 million, down 3.4% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥149 million, down 44.1% year on year, mainly due to the impact of lower inventories and other factors.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 3.4% and operating profit fell 44.1% due to higher labor costs and indirect expenses, among other factors. - FY2020-Q2RestatedAnnual report
「As a result of actively promoting sales expansion, sales were ¥2,152 million, down 0.1% year on year. On the profit side, although cost-reduction initiatives were pursued, operating profit was ¥122 million, down 14.0% year on year, mainly due to higher labor costs and indirect expenses.」
The company continued to expand medical device sales and pursue cost-reduction initiatives, but sales fell 0.1% year on year and operating profit fell 14.0% due to higher labor costs and indirect expenses, among other factors. - FY2020-Q1AdvancedAnnual report
「(Medical devices) As a result of actively promoting sales expansion, sales were ¥1,085 million, up 12.0% year on year. On the profit side, operating profit was ¥63 million, up 35.5% year on year, reflecting the effect of higher sales and the promotion of cost-reduction initiatives.」
As a result of expanding sales of medical devices, sales increased 12.0% year on year, while operating profit increased 35.5% year on year, supported by cost-reduction initiatives and other measures. - FY2019AdvancedAnnual report
「The following 3 products were commercialized in FY2018.」
The company commercialized 3 products: エンドセレクター and マジックトーム in the gastroenterology field, and オルフィス ネオ スタンダードポート in the vascular field. Medical device sales were ¥4,396 million, up 9.7% year on year, and operating profit was ¥356 million, up 121.9%. - FY2019-Q3AdvancedAnnual report
「(Medical devices) As a result of actively promoting sales expansion, revenue was ¥3,362 million, up 12.9% year on year. On the earnings side, operating profit was ¥266 million, up 109.6% year on year, due to the effect of higher revenue and the promotion of rationalization activities, among other factors.」
Revenue increased 12.9% year on year through medical device sales expansion, while operating profit increased 109.6% year on year with the contribution of rationalization activities and other measures. - FY2019-Q2AdvancedAnnual report
「As a result of actively promoting sales expansion, revenue was ¥2,154 million, up 15.2% year on year. On the earnings side, operating profit was ¥142 million, compared with an operating loss of ¥1 million in the previous fiscal year, due to the effect of higher revenue and the promotion of rationalization activities, among other factors.」
Revenue increased 15.2% year on year through medical device sales expansion, and operating profit improved from the previous year’s ¥1 million operating loss to ¥142 million. - FY2019-Q1AdvancedAnnual report
「As a result of actively promoting sales expansion, revenue was ¥968 million, up 10.6% year on year. On the earnings side, operating profit was ¥46 million, compared with an operating loss of ¥4 million in the previous fiscal year, due to the effect of higher revenue and the promotion of rationalization activities, among other factors.」
Revenue increased 10.6% year on year through medical device sales expansion, while operating profit improved from an operating loss to ¥46 million with the contribution of rationalization activities and other measures. - FY2018-Q3AdvancedAnnual report
「As a result of actively promoting sales of new products and expanding sales, revenue was ¥2,977 million, up 5.1% year on year. On the earnings side, operating profit was ¥127 million, compared with an operating loss of ¥30 million in the previous fiscal year, due to the effect of higher revenue and the promotion of rationalization activities, among other factors.」
As a result of advancing sales and sales expansion of new medical devices, revenue increased 5.1% year on year, and operating profit improved from the previous year’s ¥30 million operating loss to ¥127 million. - FY2018-Q2RestatedAnnual report
「Although we actively promoted sales expansion, revenue was ¥1,869 million, down 0.9% year on year, due to delays in the launch of some products and other factors.」
The company continues to expand medical device sales, but revenue declined 0.9% year on year due to delays in launching some products. - FY2018-Q1RestatedAnnual report
「Although we actively promoted sales expansion of medical devices, revenue was ¥875 million, down 2.7% year on year. On the earnings side, operating loss was ¥4 million, compared with an operating loss of ¥49 million in the previous fiscal year, mainly due to the cost-saving effects of rationalization and other measures.」
The company continues to expand medical device sales. Although no new milestone was presented for new products or expansion into additional product fields, the operating loss narrowed due to cost savings from rationalization and other measures. - FY2017AdvancedAnnual report
「In the medical device business, the following 4 products were commercialized in fiscal 2016.」
In fiscal 2016, the company commercialized 4 products: intravascular treatment microcatheters, guidewires, catheters for the gastrointestinal field, and artificial bone for the neurosurgery field. A catheter developed through industry-government-academia collaboration was scheduled for commercialization in fiscal 2017. - FY2017-Q3RestatedAnnual report
「Although we actively promoted sales expansion, revenue was ¥2,833 million, down 1.3% year on year, due to factors including reductions in reimbursement prices.」
The company continues its policy of expanding medical device sales, but revenue declined 1.3% year on year due to lower reimbursement prices and other factors. - FY2017-Q2RestatedAnnual report
「Although we actively promoted sales expansion of medical devices, revenue was ¥1,886 million, down 0.4% year on year, due to factors including reductions in reimbursement prices.」
The company continues its policy of expanding medical device sales, but revenue declined 0.4% year on year due to lower reimbursement prices and other factors. - FY2017-Q1RestatedAnnual report
「Although we actively promoted sales expansion of new products, revenue was ¥900 million, down 3.8% year on year, due to factors including reductions in reimbursement prices. On the earnings side, operating profit was a loss of ¥49 million, compared with operating profit of ¥67 million in the previous fiscal year, mainly because fixed costs increased at the new plant built last year.」
The company continues its policy of expanding sales of new medical devices. Meanwhile, revenue and operating profit deteriorated due to lower reimbursement prices and higher fixed costs at the new plant. - FY2016First statedAnnual report
「We will continue to identify the needs of an aging society and strengthen our product planning and sales capabilities through joint research with university hospitals and other institutions, while promoting the development, manufacture and sale of medical devices made from elastic materials that are gentle on the human body.」
The company is expanding its business scope from IVR to endoscopic treatment and orthopedic applications in neurosurgery, while strengthening product planning and sales capabilities through joint research.